Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Trevi Therapeutics Inc is a biotechnology business based in the US. Trevi Therapeutics shares (TRVI) are listed on the NASDAQ and all prices are listed in US Dollars. Trevi Therapeutics employs 23 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $1.75 |
|---|---|
| 52-week range | $0.46 - $4.68 |
| 50-day moving average | $3.53 |
| 200-day moving average | $2.12 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.28 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.75 from 2022-09-23
| 1 week (2022-09-19) | -42.81% |
|---|---|
| 1 month (2022-08-26) | -51.39% |
| 3 months (2022-06-24) | -21.17% |
| 6 months (2022-03-25) | -16.67% |
| 1 year (2021-09-24) | 21.53% |
|---|---|
| 2 years (2020-09-25) | -55.13% |
| 3 years (2019-09-26) | 4.2 |
| 5 years (2017-09-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -31.17% |
| Return on equity TTM | -79.63% |
| Profit margin | 0% |
| Book value | $1.52 |
| Market capitalisation | $139.4 million |
TTM: trailing 12 months
We're not expecting Trevi Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Trevi Therapeutics's shares have ranged in value from as little as $0.46 up to $4.683. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevi Therapeutics's is 0.1999. This would suggest that Trevi Therapeutics's shares are less volatile than average (for this exchange).
Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. .
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.